精华制药(002349) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was CNY 342,051,403.48, representing a 4.84% increase compared to CNY 326,250,102.78 in the same period last year[9] - Net profit attributable to shareholders was CNY 67,613,810.05, up 12.51% from CNY 60,093,236.10 year-on-year[9] - Basic earnings per share rose to CNY 0.0830, reflecting a 16.08% increase from CNY 0.0715 in the same quarter last year[9] - The company reported a total profit of ¥93,638,224.19, which is a 28.4% increase from ¥72,895,291.83 in the previous period[64] - Net profit for the current period was ¥83,393,533.31, representing a 24.7% increase from ¥66,846,072.45 in the previous period[64] - The profit attributable to the parent company's shareholders was ¥67,613,810.05, an increase of 12.5% compared to ¥60,093,236.10 from the previous period[64] Cash Flow - The net cash flow from operating activities improved significantly to CNY 6,726,974.68, a 144.75% increase from a negative CNY 15,033,706.80 in the previous year[9] - Cash inflow from operating activities totaled 253,135,776.32 yuan, slightly down from 255,958,813.08 yuan year-over-year[79] - Cash outflow from operating activities decreased to 246,408,801.64 yuan from 270,992,519.88 yuan, reflecting improved cost management[79] - Cash flow from financing activities generated a net inflow of 178,249,661.41 yuan, a recovery from a net outflow of -9,258,113.50 yuan in the previous period[81] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,680,494,677.49, an increase of 8.26% from CNY 3,399,701,718.30 at the end of the previous year[9] - The total liabilities, including short-term borrowings of RMB 262,275,069.50, increased from RMB 174,000,000.00, showing a rise of about 50.7%[44] - Total liabilities increased to ¥896,401,707.94, up from ¥705,268,671.55, representing a growth of approximately 27%[47] - Total equity reached ¥2,784,092,969.55, up from ¥2,694,433,046.75, marking an increase of approximately 3.3%[50] Investments and Income - Investment income surged by 496.08% to ¥4,006,087.12, primarily due to increased profits from the associated company[22] - Other income increased by 154.11% to ¥1,322,682.21, mainly from operational subsidies received by a subsidiary[22] - The company reported a non-recurring profit of CNY 7,388,134.41 after accounting for tax and minority interests[9] - Investment income from joint ventures and associates was ¥3,318,585.05, significantly higher than ¥619,631.24 in the previous period, marking a growth of 435.5%[61] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,374, with the largest shareholder holding 34.29% of the shares[13] - The company repurchased a total of 21,543,466 shares, accounting for 2.58% of the total share capital, with a total expenditure of RMB 132,183,503[30] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,322,682.21 during the reporting period[9] - The company received tax refunds of ¥1,808,023.01, a 395.93% increase compared to the previous year, due to higher export tax rebates[25] Financial Obligations - Short-term borrowings rose by 50.73% to ¥262,275,069.50 as a result of increased loans by the company and its subsidiaries[22] - The company’s long-term borrowings increased by 44.44% to ¥260,000,000.00, driven by increased loans from a subsidiary[22] - The company paid 35,000,000.00 yuan in debt repayments, reflecting ongoing financial obligations[81] Miscellaneous - The company has no reported violations regarding external guarantees during the reporting period[35] - There were no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[36] - The report indicates that the company has not applied new financial instrument standards or new lease standards retrospectively[100] - The company has not undergone an audit for the first quarter report[103]